Raymond Low - SciClone Pharmaceuticals Vice President - Finance, Controller
President
Mr. Raymond A. Low is Vice President Finance, Controller of Sciclone Pharmaceuticals, Inc. He joined SciClone as Vice President, Finance and Controller in October 2013. Prior to joining SciClone, from 2009 to 2013, Mr. Low served as Chief Financial Officer, and from 2005 to 2009 as Corporationrationrate Controller at AXT, Inc., a publicly traded manufacturer of high performance semiconductor substrates. From 2002 to 2004, Mr. Low was Corporationrationrate Controller of Therasense, Inc., a health care products company. Mr. Low is a California certified public accountant and a member of the California Society of CPAs. He is a past member of the Chartered Institute of Management Accountants in the United Kingdom since 2013.
| Age | 57 |
| Tenure | 11 years |
| Professional Marks | MBA |
| Phone | 650 358-3456 |
| Web | www.sciclone.com |
SciClone Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.16 % which means that it generated a profit of $0.16 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.19 %, meaning that it created $0.19 on every $100 dollars invested by stockholders. SciClone Pharmaceuticals' management efficiency ratios could be used to measure how well SciClone Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 2.73 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. SciClone Pharmaceuticals has a current ratio of 8.19, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist SciClone Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, SciClone Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like SciClone Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for SciClone to invest in growth at high rates of return. When we think about SciClone Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Jill Barnett | SunOpta | 50 | |
| David Gibbs | Yum Brands | 61 | |
| George Karolis | Asbury Automotive Group | 42 | |
| Christian Campbell | Yum Brands | 63 | |
| William Stax | Asbury Automotive Group | 48 | |
| Patrick Guido | Asbury Automotive Group | 47 | |
| Heather Kaminetsky | MYT Netherlands Parent | N/A | |
| David Gordon | The Cheesecake Factory | 59 | |
| Jonathan Blum | Yum Brands | 56 | |
| George Villasana | Asbury Automotive Group | 56 | |
| Sean Goodman | Asbury Automotive Group | 53 | |
| Jed Milstein | Asbury Automotive Group | 55 | |
| Max Byfuglin | The Cheesecake Factory | 70 | |
| Matthew Clark | The Cheesecake Factory | 54 | |
| Gerard Versteegh | SunOpta | 54 | |
| Keith Carango | The Cheesecake Factory | 62 | |
| John Hartman | Asbury Automotive Group | 55 | |
| Michael Welch | Asbury Automotive Group | 49 | |
| James Gratzek | SunOpta | 51 | |
| Brian Carmichall | El Pollo Loco | 60 | |
| Cheryl Slomann | The Cheesecake Factory | 58 | |
Management Performance
| Return On Equity | 0.19 | |||
| Return On Asset | 0.16 |
SciClone Pharmaceuticals Leadership Team
Elected by the shareholders, the SciClone Pharmaceuticals' board of directors comprises two types of representatives: SciClone Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SciClone. The board's role is to monitor SciClone Pharmaceuticals' management team and ensure that shareholders' interests are well served. SciClone Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SciClone Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charles Meng, VP of Compliance and General Counsel | ||
| Richard Hawkins, Independent Director | ||
| Gregg Lapointe, Independent Director | ||
| Hong Zhao, CEO of China Operations | ||
| Wilson Cheung, CFO, Sr. VP of Fin. and Secretary | ||
| Nancy Chang, Director | ||
| Anthony Lapointe, Independent Director | ||
| Lan Xie, VP of Fin. and CFO of China Operations | ||
| Raymond Low, Vice President - Finance, Controller | ||
| Robert King, Senior Vice President - Product Development and Supply Chain | ||
| Simon Li, Independent Director | ||
| Jon Saxe, Independent Chairman of the Board | ||
| Friedhelm Blobel, CEO and President Executive Director and Member of Bus. Devel. Committee |
SciClone Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SciClone Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.19 | |||
| Return On Asset | 0.16 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 25.82 % | |||
| Current Valuation | 422 M | |||
| Shares Outstanding | 52.19 M | |||
| Shares Owned By Insiders | 10.03 % | |||
| Shares Owned By Institutions | 79.96 % | |||
| Number Of Shares Shorted | 1.21 M | |||
| Price To Earning | 13.75 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards SciClone Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, SciClone Pharmaceuticals' short interest history, or implied volatility extrapolated from SciClone Pharmaceuticals options trading.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Consideration for investing in SciClone Stock
If you are still planning to invest in SciClone Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the SciClone Pharmaceuticals' history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |